LLY - Eli Lilly and Company Последние новости | Finranks

15.10.2026

Polen Focus Growth Portfolio Q3 2026 Portfolio Update

In Q3 2026, the Portfolio returned 4.46% (net of fees) compared to 0.92% for the Index. Top relative contributors to the Portfolio's performance included ServiceNow, Shopify and Microsoft. By contrast, the largest relative detractors in the quarter were Nvidia, Apple (not owned) and Lam Research.

13.10.2026

Here's Why Eli Lilly (LLY) Fell More Than Broader Market

Eli Lilly (LLY) reached $1 at the closing of the latest trading day, reflecting a -1.04% change compared to its last close.

13.10.2026

Bristol Myers Squibb vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026?

Bristol Myers Squibb offers a significant yield and recovery in net income, supported by its strong oncology and cardiovascular segments. Eli Lilly & Co. is experiencing massive growth in revenue and profitability, driven by its leadership in the obesity and diabetes treatment markets.

13.10.2026

Prediction: Eli Lilly Could Have More Room to Grow Than Its Valuation Suggests

Eli Lilly trades at a premium multiple, yet its revenue growth dwarfs every major pharma peer by a wide margin. Whether that gap justifies buying shares near all-time highs depends on one critical assumption about Lilly's pipeline.

13.10.2026

Johnson & Johnson Drops 5% as One-Time Charges Overshadow Raised Full-Year Outlook; Eli Lilly Dips, Pfizer Sits Out the Selloff

Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) stock is at $249.55, down 5% early in the session. The company raised its full-year outlook in the same release that showed its reported profit falling under one-time charges.

13.10.2026

Eli Lilly Reports Earnings on Oct. 29. Here's Why the Retatrutide Story Matters More Than the Quarter.

Retatrutide could become a major long-term growth driver. Lilly plans to seek FDA approval in early 2027.

13.10.2026

Eli Lilly Expects Up to $87 Billion in 2026 Revenue. Here's Why the Stock Still Looks Undervalued.

Eli Lilly dominates the weight loss drug market and is delivering explosive revenue growth. The company has a strong pipeline, too, which may broaden its weight loss portfolio in the coming years.

Видео

22.09.2026

Positive

Ken Langone on Eli Lilly: Could be a $2,000 stock in the next 3-4 years

18.09.2026

Positive

40% of U.S. Adults to Use GLP-1s? Raul Shah on LLY, NVO & Weight Loss "Mania"

Повышения / Понижения рейтинга

Тикер	Фирма	Изменение рейтинга	Целевая цена	Дата
LLY	Berenberg	Buy	undefined >> $1,400	September 15th 2026

Пресс-релизы

09.10.2026

New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) advance understanding of the interconnected immune and metabolic biology in adults with psoriasis and obesity

Exploratory data presented at Fall Clinical 2026 showed broader biomarker changes with Taltz and Zepbound vs. Taltz alone as early as Week 12 in first-of-its-kind TOGETHER-PsO study INDIANAPOLIS, Oct. 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new exploratory data from the TOGETHER-PsO Phase 3b clinical trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) compared with Taltz alone in adults with moderate-to-severe plaque psoriasis and obesity or overweight with at least one additional weight-related comorbid condition.

Eli Lilly and Company (LLY)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Контакты

Мы в соцсетях

Eli Lilly and Company (LLY)

Polen Focus Growth Portfolio Q3 2026 Portfolio Update

Here's Why Eli Lilly (LLY) Fell More Than Broader Market

Bristol Myers Squibb vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026?

Prediction: Eli Lilly Could Have More Room to Grow Than Its Valuation Suggests

Johnson & Johnson Drops 5% as One-Time Charges Overshadow Raised Full-Year Outlook; Eli Lilly Dips, Pfizer Sits Out the Selloff

Eli Lilly Reports Earnings on Oct. 29. Here's Why the Retatrutide Story Matters More Than the Quarter.